Corcept Therapeutics Director James N. Wilson Reports Sale of $1.15 Million in Common Shares
Bitget2026/10/16 22:25- Corcept Therapeutics director James N. Wilson sold 10,000 common shares on Oct. 15, 2026.
- Sales comprised 6,654 shares at $114.4751, 3,046 at $115.3895 and 300 at $116.2967.
- The James N. Wilson and Pamela D. Wilson Trust held 1,054,543 common shares following the sales.
- Two grantor retained annuity trusts held another 400,000 common shares indirectly.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Microsoft Beats Nvidia for the First Time Since 2025: So Why Is MSFT Stock Falling?
Gunnison hits rich copper and zinc in Arizona
EIA expects Brent crude spot prices to remain at $100 per barrel for the rest of the year and raises the average price forecasts for this year and next.
The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

